Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
Multidrug resistance in MCF-7/Adr human breast cancer cells is mediated by several mechanisms including overexpression of the MDR1 gene product, P-glycoprotein and glutathione-related detoxifying enzymes. Mutations in the p53 tumor suppressor protein have been reported to play a role in the development of resistance to DNA damaging agents in several human cancer cells. In the present study we have assessed the mutational status of the p53 protein and its expression levels, degree of stability and cellular localization to investigate whether it is involved in modulating multidrug resistance in MCF-7/Adr cells compared to sensitive MCF-7 cells. As revealed by immunofluorescence microscopy using the anti-p53 mouse monoclonal antibody DO-1, wild-type p53 is sequestered in the cytoplasm of MCF-7 cells, whereas in MCF-7/Adr cells, the protein is localized in the nucleus. The sequencing of full-length p53 cDNA revealed a 21 bp deletion in its one of the four conserved regions within the conformational domain, spanning codons 126-133 at exon five, in MCF-7/Adr cells. Moreover, detection of ThaI polymorphism of codon 72 showed that MCF-7 cells predominantly express wild-type p53 with proline, while mutated p53 in MCF-7/Adr cells contains an arginine residue at codon 72. In addition, we demonstrate that the half-life of p53 in MCF-7 cells is less than 30 min while the mutated protein is more stable; its half-life is about 4 h in MCF-7/Adr cells. Thus, this study demonstrates that the deletion of codons 126-133 in p53 causes increased stability, overexpression and nuclear localization of the protein in multidrug resistant MCF-7/Adr cells, and further suggests that mutated p53 might be involved in the development of multidrug resistance in this cell line.
Ogretmen
B
B
Department of Experimental Oncology, Medical University of South Carolina, Charleston 29425, USA.
Safa
A R
AR
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal; D001483:Base Sequence; D001943:Breast Neoplasms; D002470:Cell Survival / Q000187:drug effects*; D003062:Codon; D017124:Conserved Sequence; D017931:DNA Primers; D018076:DNA, Complementary; D004317:Doxorubicin / Q000633:toxicity*; D018432:Drug Resistance, Multiple; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D016158:Genes, p53; D006801:Humans; D051379:Mice; D016297:Mutagenesis, Site-Directed; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011994:Recombinant Proteins / Q000096:biosynthesis; D017384:Sequence Deletion; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D000911:Antibodies, Monoclonal; D003062:Codon; D017931:DNA Primers; D018076:DNA, Complementary; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D004317:Doxorubicin